Shots:

• The P-III BLOCKSTONE study results involves assessing of Xofluza vs PBO in children & adults diagnosed with influenza- confirmed by rapid influenza diagnostic test in Japan
• The P-III BLOCKSTONE study results: household members infected with flu (1.9% vs 13.6%); well tolerated; no new signals are observed; conducted by Shionogi
• Xofluza is oral therapy to treat influenza in both healthy people with flu & at high risk of flu- evaluated in CAPSTONE-1 & 2 study respectively and is approved in Japan & US with its expected FDA’s approval for the treatment of flu in patients with asthma- chronic lung disease- morbid obesity and heart disease by Nov 04- 2019

Ref: Roche | Image: Roche